CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Rituximabdrug
Likely dose
1000 mg rituximab intravenously on day 0 and day 14AI-extracted
Key inclusion· 2
  • ✓Confirmed diagnosis of bullous pemphigoid by clinical, histologic, and immunological criteria
  • ✓Ongoing disease activity while on at least 17.5 mg/day prednisone
Key exclusion· 1
  • ✕Current use of other immunosuppressive agents (azathioprine, cyclophosphamide, or mycophenolate mofetil) within the last 4 weeks

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00286325
NCT00286325Phase 2Completed
CompareCT.gov

Rituximab in the Treatment of Patients With Bullous Pemphigoid

Duke University·interventional·Posted Feb 3, 2006·Updated Apr 11, 2013

In Brief

A Phase 2 clinical trial evaluating Rituximab for Bullous Pemphigoid. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBullous Pemphigoid
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 3, 2006
Enrollment StartMar 1, 2005
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 20.4 years ago

Interventions

Rituximabdrug

Infusion of 1000 mg of rituximab on day 0 and day 14